ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO636

The Impact of Desmopressin on Native Kidney Biopsy Complications

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Leclerc, Simon, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
  • Elftouh, Naoual, Hôpital Maisonneuve Rosemont, Montreal, Quebec, Canada
  • Lafrance, Jean-Philippe, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
  • Nadeau-Fredette, Annie-Claire, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
  • Pichette, Vincent, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
  • Laurin, Louis-Philippe, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
Background

As bleeding is a feared complication of native kidney biopsy (NKB), nephrologists often prescribe desmopressin in an attempt to lower its occurrence, especially for patients with reduced estimated glomerular filtration rate (eGFR) at risk of uremia-related platelet dysfunction. However, only one randomized study has analyzed its effect before NKB on patients with eGFR >60 mL/min/m2whereas retrospective studies on patients with eGFR <60 mL/min/m2are contradictory.

Methods

This study aims to evaluate the impact of desmopressin on complications after NKB. We reviewed medical records of every adult patient who had a NKB at our tertiary teaching hospital from April 2013 to April 2018. We collected data concerning the medical history of each patient and their clinical parameters before and after each NKB. We used multivariate logistic regressions to evaluate the effect of desmopressin on the occurrence of hemoglobin fall, transfusions, hypotension, acute kidney injury (AKI), hematomas and additional radiologic examinations.

Results

Among the 413 NKB analyzed, 79.4% were done after a dose of desmopressin. Patients who received desmopressin had more severe chronic kidney disease at baseline (eGFR 39 vs 54 mL/min/m2; p=0.0003) and were more often hospitalized before the biopsy (48% vs 32%; p=0.009). There was a tendency for a reduction in symptomatic hematomas (OR=0.34; 95%CI: 0.11-1.19; p=0.08) and a significant reduction of post-biopsy additional radiologic examinations (OR=0.22; 95%CI: 0.07-0.73; p=0.01) in the desmopressin group. Desmopressin had a neutral effect on other complications (see table) and on hyponatremia.

Conclusion

Our results were affected by an indication bias, because sicker patients were more likely to receive desmopressin and IV fluids causing hemodilution. However, after adjustment for potential cofounders, desmopressin seems to reduce post-biopsy symptomatic hematomas and additional radiologic examinations, implying important clinical and financial benefits.

 ORCI 95%p
Hemoglobin fall > 151.54[0.78;3.23]0.23
Hemoglobin fall > 201.29[0.58;4.36]0.43
Transfusion1.63[0.19;8.59]0.46
Radiologic hematomas0.86[0.39;2.01]0.70
Hypotension1.08[0.41;3.11]0.88
AKI2.04[0.35;38.72]0.51